(Q48105762)

English

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

Gobbini MI

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Smith ME

2

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Richert ND

3

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Frank JA

4

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

McFarland HF

5

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

publication date

1 September 1999

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Journal of Neuroimmunology

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

99

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

1

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

142-149

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic Mechanisms and Therapy in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Side-effects of intravenous cyclophosphamide pulse therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

24-month follow-up of multiple sclerosis patients treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance in monitoring the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide: Effect on Experimental Allergic Encephalomyelitis in Lewis Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimisation of cyclophosphamide therapy in systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recognition and management of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

[Blood-brain barrier and the penetration of cytostatic drugs]

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2899%2900039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0165-5728(99)00039-9

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2018

http://europepmc.org/abstract/MED/10496187

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48105762&oldid=2184901475"